The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. This year’s metric has recorded a Price increase of 69.65%. However, over the past six months, we’ve seen a weaker performance of 29.30%. The price of TSHA fallen by 102.41% over the last 30 days. And in the last five days, it has surged by 25.43%.
Taysha Gene Therapies Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $4.32 on 06/13/24, while the lowest price for the same duration was marked at $1.05 on 04/09/25.
52-week price history of TSHA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Taysha Gene Therapies Inc’s current trading price is -32.06% away from its 52-week high, while its distance from the 52-week low is 179.52%. The stock’s price range during this period has varied between$1.05 and $4.32. The Taysha Gene Therapies Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.41 million for the day, a figure considerably lower than their average daily volume of 2.61 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Taysha Gene Therapies Inc (TSHA) has experienced a quarterly rise of 78.96% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 630.04M and boasts a workforce of 73 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.73, with a change in price of +0.98. Similarly, Taysha Gene Therapies Inc recorded 2,400,737 in trading volume during the last 100 days, posting a change of +53.28%.
TSHA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TSHA stands at 1.13. Similarly, the long-term debt-to-equity ratio is also 1.09.
TSHA Stock Stochastic Average
As of today, Taysha Gene Therapies Inc’s raw stochastic average for the last 50 days stands at 95.38%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 92.86%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 94.00% and 90.97%, respectively.
